DTI评价猪急性心肌梗死再灌注治疗的实验研究

目的:探讨应用多普勒组织运动成像技术(DTI,Dopplar Tissue Motion Imaging)评价实验猪心肌梗死再灌注治疗后左室功能变化的价值。方法:取试验用家猪24头,随机分成2组,A组(10头)B组(14头)。A组作为对照组,未做任何处置,只是在相应时间点获取数据。B组实验猪经开胸,于前降支起始1 cm处,放置特制银夹,可以缓慢夹闭前降支血管,银夹自放置至完全闭合需6小时,9小时后再次开胸,取出银夹,进行心肌再灌注。A组与B组夹闭前、夹闭后6小时造影检查确定前降支完全闭塞、9小时闭塞状态取出银夹、12小时再灌注3小时进行常规超声心动图检查和DTI,获取对照组和模型组夹闭前、夹闭后6小时、9小时、12小时的左室舒张末期内径Edd(Left Ventricular End Diastolic Diameter)、收缩末期内径Esd(Left Ventricular End Systolic Diameter)、每搏输出量SV(cardiac stroke volume)、射血分数EF(ejection fraction)、短轴缩短率Fs(Fraction Shortening);舒张期二尖瓣前向血流频谱E峰、A峰、E/A等常规参数。转TVI(Tissue Velocity Imaging)模式下DTI测量二尖瓣环组织运动参数:收缩期峰值速度Sa、舒张早期峰值速度Ea、舒张晚期峰值速度Aa、及Ea/Aa。结果:1).B组实验猪在夹闭6小时、9小时、12小时DTI所测数据Sa峰值变化比常规数据变化明显(P0.01)2)。DTI所测数据Ea、Aa、Ea/Aa变化较舒张期二尖瓣前向血流数据E峰、A峰、E/A变化出现早。3).病理显示夹闭9小时时前壁心肌出现坏死,心肌细胞被破坏及炎细胞浸润。结论:DTI可以准确及时评价实验猪急性心肌梗死再灌注治疗左室功能的变化。     

诺迪康对急性心肌缺血和心衰大鼠血流动力学的影响

目的：研究诺迪康（rhodiola）对急性心肌缺血和心力衰竭大鼠血流动力学的影响,探讨该药的血流动力学作用机制。方法：采用垂体后叶素（Pit）诱发大鼠急性心肌缺血,20min后用戊巴比妥钠（PS）致急性心力衰竭,经Powerlab／4SP和BL-420E多道生物信号分析系统监测血流动力学。结果：①Rhodiola明显对抗Pit诱导的急性心肌缺血大鼠心电图ST段的偏移、HR的降低厦LVEDP的升高;＋dP／dtmax．dP／dtmax均高于NS组．该作用具有剂量依赖性。②和对照组相比,rhodiola能通过改善血流动力学对抗PS导致的急性心衰。结论：rhodiola能改善心肌缺血和心力衰竭大鼠的血流动力学。     

强迫跑步等复合因素对Wistar大鼠左心室血流动力学的影响

目的　检测控食、强迫跑步及大剂量心得安等复合因素对Wistar大鼠左心室血流动力学的影响。方法　实验组实验全过程采用控食及强迫跑步的方法造模 ,第 17天起每日灌服心得安溶液 ,连续 4d。第 2 1天测定血流动力学。然后将余下的大鼠再平均分为药物反证组和鉴别反证组。药物反证组灌服补心气口服液 ,连续 12d。鉴别反证组灌服滋心阴口服液 ,连续 12d ,最后测定血流动力学。结果　实验组最大心室内压、平均 +dp dtmax、平均Vpm等指标均小于正常组 ,且差异有显著性。最小心室内压、平均 dp dtmax等指标均大于正常组 ,差异亦有显著性。结论　控食、强迫跑步及大剂量心得安等复合因素可抑制Wistar大鼠的心功能     

急性心肌梗死的急诊诊疗体会

急性心肌梗死（AMI）是指在冠状动脉粥样硬化伴有粥样斑块出血、血栓形成或冠状动脉痉挛导致管腔急性闭塞和血流中断,使血栓血管供应的心肌出现严重而持久的急性缺血,从而导致心肌细胞坏死。是急诊科常见的急危重症,须紧急救治。现将2001-2006年本院急诊科院前急救后送人心内科治疗的AMI43例,结合有关文献资料报告如下。     

硝酸甘油对急性心肌梗死病人心律失常的作用

硝酸甘油对急性心肌梗死的疗效肯定,其有效作用主要是改善心肌供血及心脏泵血功能,但对急性心肌梗死并发心律失常的作用报道较少。笔者总结了近7年来使用硝酸甘油治疗急性心肌梗死病人90例,疗效确切。现报道如下。     

不同海拔高度对健康成年男性心脏血流动力学和心电图的影响

目的:监测中国南极冰盖考察预选队员心血管系统随海拔增高的变化,探讨筛查低氧易感队员和急性高原病的防治。方法:用无创血流动力学监护仪和十二导联心电图机,在北京(40 m)、拉萨(3 650 m)、羊八井(4 300 m)对第25次和26次南极冰盖考察预选队员心血管功能进行连续动态性监测。结果:随着海拔的增高,心率、收缩压、舒张压、平均动脉压、外周血管阻力、外周血管阻力指数显著升高(P0.05),心输出量、心指数、搏出量、搏出指数、加速度指数、速度指数、左心射血时间显著降低(P0.05),预射血期呈降低趋势(P0.05)。结论:随着海拔的增高,预选队员的外周血管阻力显著升高,左心泵血和收缩功能减弱且与Q-TC间期呈负相关。     

急性心肌梗死的静脉溶栓治疗

溶栓是治疗急性心肌梗死最有前途的方法。梗死相关动脉的尽快开通是保护心肌、提高患生存率的关键。本旨在概述已得到认可的溶栓剂和相关的临床试验,包括链激酶、尿激酶、重组组织型纤溶酶原激活剂等。辅助治疗如肝素、水蛭素、血小板糖蛋白Ⅱb／Ⅲa受体拮抗剂也在本综述之列。     

心肌带收缩率与急性心肌梗死患者左心室收缩功能关系

目的:急性前壁心肌梗死明显影响室间隔收缩率和左心室射血分数(left ventricular ejection fraction LVEF)。本文旨在探讨心肌带降段及升段收缩率与急性前壁心肌梗死患者LVEF的相关性。方法:收集2015年4月-2017年2月在心内科住院的急性前壁心肌梗死患者36例,正常对照组患者39例。所有患者取左心室长轴M型超声心动图,测量室间隔收缩率、升段收缩率及降段收缩率。心肌梗死左心室射血分数采用双平面Simpson's法计算。结果:与正常对照组相比,心肌梗死组患者舒张末期心肌带升段厚度没有统计学差异(P=0.69),收缩末期升段厚度(P=0.014)更薄、升段收缩率(P0.01)明显降低;心肌梗死组舒张末期降段厚度(P0.01)更薄、收缩末期降段厚度(P0.01)更薄、降段收缩率(P0.01)明显降低;心肌梗死组左心室射血分数与降段收缩率(r~2=0.13,P=0.026)、室间隔增厚率(r~2=0.19,P0.01)呈正相关,与升段收缩率没有相关性(P0.05)。正常对照组左心室射血分数与室间隔增厚率、降段增厚率及升段增厚率无相关性。经过相关分析,筛选出与心肌梗死LVEF的相关因素,进一步经逐步回归分析,得多元线性回归方程为LVEF=48.206+18.914*LVDD(cm)-25.414*LVSD(cm)。结论:急性前壁心肌梗死室间隔降段收缩率明显受损,与左心室射血分数降低有关。多元线性回归方程可估算前壁心肌梗死LVEF。     

整体护理对老年急性心肌梗死病人康复的作用

急性心肌梗死患者发病急,病情凶险,心理复杂,压力大,对疾病恢复造成极大的负面影响。近年来国内外广泛开展早期心脏疾病的康复治疗,大量资料表明,无并发症的心肌梗死患者,早期活动对远期预后可产生有益影响。我们针对老年急性心肌梗死患者的特点,细心观察老年急性心肌梗死在疾病各阶段的心理状况,由责任护士对患者进行康复指导,     

血毒清联合杂合肾脏替代治疗对重症脓毒症的疗效、血流动力学和预后干预作用的研究

目的探讨血毒清联合杂合肾脏替代治疗（HRRT）重症脓毒症的效果及对血流动力学、预后的影响。 方法选取2017年3月至2019年8月十堰市太和医院重症脓毒症患者135例,在常规治疗基础上,按简单随机化法分为血毒清组、HHRT组和血毒清联合HRRT组（联合组）,每组45例,治疗5 d。治疗前和治疗5 d后序贯器官衰竭评分（SOFA）、急性生理学与慢性健康状况评分系统Ⅱ评分（APACHEⅡ）、炎症因子指标[白细胞介素-10（IL-10）、IL-6、降钙素原（PCT）、C反应蛋白（CRP）]水平、血流动力学指标[全身血管阻力指数（SVRI）、血管外肺水指数（EVLWI）、胸腔内血容积指数（ITBVI）、心指数（CI）]及重症监护室（ICU）住院时间比较采用配对t检验,多组间差异采用方差分析,组间两两比较采用LSD-t检验,3组28 d病死率采用c²检验。 结果治疗5 d后,与联合组比较,HHRT组和血毒清组SOFA评分[（4.29±1.17）分比（6.15±1.39）分、（7.03±1.52）分]、APACHEⅡ评分[（11.68±2.12）分比（14.26±3.04）分、（15.17±2.85）分]、血清IL-10 [（36.61±6.50）μg/L比（42.75±7.42） μg/ L、（45.06±8.37） μg / L]、IL-6 [（130.26±41.04） pg/ mL比（169.84±46.75） pg/ mL、（178.36±50.91） pg/ mL]、PCT [（0.87±0.29） ng/mL比（1.96±0.47） ng/mL、（2.24±0.53）ng/mL]、CRP [（34.93±9.71） mg/ L比（51.67±10.32）mg/L、（56.79±11.82）mg/L] 、EVLWI [（4.12±1.38）mL/kg比（5.38±1.69） mL/ kg、（6.04±1.85）mL/kg]降低,而SVRI [（2079.54±124.75） dyn·s·cm^{- 5}·m²比（1865.37±109.38） dyn·s·cm^-5·m²、（1796.28±131.75）dyn·s·cm^-5·m²]、ITBVI [（1189.40±92.36） mL/ m²比（986.97±75.32）mL/m²、（902.37±68.64） mL/ m²]、CI [（4.26±0.65） L·min^-1·m^-2比（3.83±0.58）L·min^-1·m^-2、（3.67±0.53）L·min^-1·m^-2]均升高,差异均有统计学意义（P < 0.05）。与联合组比较,HHRT组和血毒清组ICU住院时间[（14.82±4.40）d比（17.20±3.47）d、（18.46±4.25）d]缩短（P < 0.05）。 结论血毒清联合HRRT治疗重症脓毒症,对减少炎性因子水平,调节血流动力学具有一定作用,能够缩短ICU住院时间。     

Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction

Objectives: To analyze the predictive value of cardiac collagen metabolism “in vivo" in patients with myocardial infarction (MI) treated with percutaneous coronary intervention (PCI). Design: Forty-five patients (age 66 ± 8.27) underwent biochemical analysis for cardiac collagen metabolism (groups A, B and C); 30 patients with their first MI were treated with successful PCI (group A; n = 30), group B (n = 5) were MI patients with unsuccessful PCI. Group C were patients without MI (n = 10), they underwent elective diagnostic coronary angiography only. The collagen metabolism was analyzed in acute and subacute MI phases by using serum blood markers: the carboxy-terminal propeptide of type I procollagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP) and carboxy-terminal telopeptide of type I collagen (ICTP). Furthermore, the ejection fraction (EF) and left ventricular end-diastolic volume maximal changes in the course of 6 months were measured by echocardiography. Results: A significant increase of both PICP and PIIINP on day 4 following MI was detected. Furthermore, PICP and PIIINP level assessed on the 30th day was significantly higher in the PCI unsuccessful group versus successful group. PICP level on day 4 above 110 ug/l and PIIINP level above 4 ug/l was significantly often found in the subgroup of patients with the EF improvement less than 10% or worsening and with significant left ventricular dilatation during 6 months follow-up. Cardiac catheterization itself does not affect collagen metabolism. Conclusion: We concluded that collagen metabolism markers enable to study in vivo the MI healing and to predict left ventricular functional and volume changes.     

Association of increased oncostatin M with adverse left ventricular remodeling in patients with myocardial infarction

BackgroundThe study of laboratory biomarkers that reflect the development of adverse cardiovascular events in the postinfarction period is of current relevance. The aim of the present study was evaluation of oncostatin M (OSM) concentration changes in the early and late stages of myocardial infarction and evaluation of the possibility of its use in prediction of adverse left ventricular (LV) remodeling in patients with myocardial infarction with ST-elevated segment (STEMI).MethodsThe study involved 31 patients with STEMI admitted in the first 24 hours after the onset of MI and 30 patients with chronic coronary artery disease as a control group. Echocardiographic study was performed on day 3 and in 6 months after STEMI. The serum levels of biomarkers were evaluated on the day of hospital admission and 6 months after MI using multiplex immunoassay.ResultsOSM level increased during the first 24 h after the onset of the disease, with the following decrease in 6 months. OSM concentration at admission had correlated with echocardiography parameters and Nt-proBNP, troponin I, CK-MB levels. Our study has demonstrated association of the increased levels of OSM at the early stages of STEMI with development of the adverse LV remodeling in 6 months after the event.ConclusionsElevation of OSM levels in the first 24 h after STEMI is associated with the development of the adverse LV remodeling in the long-term post-infarction period.     

Cardiac sympathetic afferent ablation to prevent ventricular arrhythmia complicating acute myocardial infarction by inhibiting activated astrocytes

Enhanced cardiac sympathetic afferent reflex (CSAR) contributes to ventricular arrhythmia (VA) after acute myocardial infarction (AMI). However, central regulation mechanisms remain unknown. The aim of this study was to investigate whether local cardiac sympathetic afferent ablation (LCSAA) could reduce VA by inhibiting activated astrocytes in the hypothalamus paraventricular (PVN) in an AMI rat model. The rats were randomly divided into AMI, AMI + BD (baroreceptor denervation), AMI + LCSAA and AMI + BD+ LCSAA groups. Before the generation of AMI, BD and (or) LCSAA were performed. At 24 h after AMI, the incidence and duration of VA in AMI + LCSAA group and AMI + BD + LCSAA group were significantly reduced than AMI group (P < 0.05). Furthermore, LCSAA significantly reduced GFAP (a marker for activated astrocytes) positive cells and their projections as well as the level of TNF‐α and IL‐6 in the PVN of AMI + LCSAA group and AMI + BD+ LCSAA group, along with the decrease of neuronal activation in PVN and sympathetic nerve activity (P < 0.05). but BD had no obvious difference between AMI + LCSAA and AMI + BD + LCSAA group (P > 0.05). Therefore, LCSAA could decrease sympathoexcitation and VA occurrence in AMI rats by inhibiting astrocyte and neuronal activation in the PVN. Our study demonstrates that activated astrocytes may play an important role on CSAR in AMI.     

急性心肌梗塞静脉溶栓后冠脉再通对左心室功能的影响

为进一步探讨静脉溶栓后冠脉再通对左室功能的有益影响,回顾性分析了88例静脉溶栓急性心肌梗塞(AMI)病人的二维超声心动图和部分病人的冠脉造影资料。根据溶栓再通标准分为再通组和未通组。在AMI发病后平均24.8±11.6天和22.9±24.4天分别进行了心超和冠造检查,观察室壁运动情况并测量左室射血分数(LVEF)。结果显示:未通组LVEF明显低于再通组,而室壁运动异常积分却显著高于再通组。左室扩大和室壁瘤的发生上,两组未发现有统计学差异。以上结果提示:AMI静脉溶栓使冠脉再通对左室功能和室壁运动障碍的改善起到有益的作用。     

Functional suppression of Epiregulin impairs angiogenesis and aggravates left ventricular remodeling by disrupting the extracellular-signal-regulated kinase1/2 signaling pathway in rats after acute myocardial infarction

Acute myocardial infarction (AMI), a severe consequence of coronary atherosclerotic heart disease, is often associated with high mortality and morbidity. Emerging evidence have shown that the inhibition of the extracellular-signal-regulated kinase (ERK) signaling pathway appears to protect against AMI. Epiregulin (EREG) is an autocrine growth factor that is believed to activate the MEK/ERK signaling pathway. Therefore, the aim of the present study was to determine the expression patterns of EREG in AMI and to further study its effects on AMI induced experimentally in rats focusing on angiogenesis and left ventricular remodeling. Microarray-based gene expression profiling of AMI was used to identify differentially expressed genes. To understand the biological significance of EREG and whether it is involved in AMI disease through the ERK1/2 signaling pathway, rats after AMI were treated with small interfering RNA (siRNA) against EREG, an ERK1/2 pathway inhibitor, PD98059, or both of them. The microarray data sets GSE66360 and GSE46395 showed that EREG was robustly induced in AMI. Both siRNA-mediated depletion of EREG and PD98059 treatment were shown to significantly increase infarct size and left ventricular cardiomyocyte loss and enhance left ventricular remodeling. In addition, we also found that the ERK1/2 signaling pathway was inhibited following siRNA-mediated EREG inhibition and PD98059 could enhance the effects of EREG inhibition on AMI. In conclusion, these findings highlight that the silencing of EREG inhibits angiogenesis and promotes left ventricular remodeling by disrupting the ERK1/2 signaling pathway, providing a novel therapeutic target for limiting AMI.     

The natriuretic peptide time-course in end-stage heart failure patients supported by left ventricular assist device implant: focus on NT-proCNP

This study aimed to evaluate left ventricular assist device (LVAD) effects on natriuretic peptide (NP) prohormone plasma levels in end-stage heart failure (HF) patients, especially NT-proCNP, in order to better characterize the NP system during hemodynamic recovery by LVAD. HF patients (n=17, NYHA III-IV) undergoing LVAD were studied: 6 died of multi-organ failure syndrome (NS) and 11 survived (S). Total sequential organ failure assessment (t-SOFA) score and blood samples were obtained at admission (T1) and at 24, 72h and 1, 2, 4 weeks (T2-T6) after LVAD. In S, NT-proANP and NT-proCNP significantly increased at 24h after implantation, reaching a reduction to basal levels at 4 weeks following LVAD [NT-proANP: T1 vs. T2 p=0.017, NT-proCNP: T1 vs. T2 p=0.028, T1 vs. T3 p=0.043]. Elevated NT-proBNP plasma levels were observed at all times. In NS, NP plasma levels sustained higher with respect to S. No statistical variation was observed for NT-proCNP and NT-proANP in S and NS while NT-proBNP reached significant differences at T4 in NS. Considering S+NS, only NT-proCNP strongly correlated with t-SOFA score at T1 (rho=0.554, p=0.04) while subdividing patients NT-proCNP positively correlated in NS with t-SOFA score (rho=0.988, p=0.002) only at T4. In NS a correlation between NT-proCNP and NT-proBNP at T1 was observed (rho=-0.900, p=0.037). Both IL-6 and TNF-alpha sustained higher in NS patients than in S; in particular, statistical significance was observed for IL-6. The study of new peptides, such as NT-proCNP, would provide additional information for identifying patients who are more likely to recover.     

Haemolysis as a first sign of thromboembolic event and acute pump thrombosis in patients with the continuous-flow left ventricular assist device HeartMate II

Background

Despite advances in pump technology, thromboembolic events/acute pump thrombosis remain potentially life-threatening complications in patients with continuous-flow left ventricular assist devices (CF-LVAD). We sought to determine early signs of thromboembolic event/pump thrombosis in patients with CF-LVAD, which could lead to earlier intervention.

Methods

We analysed all HeartMate II recipients (n = 40) in our centre between December 2006 and July 2013. Thromboembolic event/pump thrombosis was defined as a transient ischaemic attack (TIA), ischaemic cerebrovascular accident (CVA), or pump thrombosis.

Results

During median LVAD support of 336 days [IQR: 182–808], 8 (20 %) patients developed a thromboembolic event/pump thrombosis (six TIA/CVA, two pump thromboses). At the time of the thromboembolic event/pump thrombosis, significantly higher pump power was seen compared with the no-thrombosis group (8.2 ± 3.0 vs. 6.4 ± 1.4 W, p = 0.02), as well as a trend towards a lower pulse index (4.1 ± 1.5 vs. 5.0 ± 1.0, p = 0.05) and a trend towards higher pump flow (5.7 ± 1.0 vs. 4.9 ± 1.9 L m, p = 0.06).The thrombosis group had a more than fourfold higher lactate dehydrogenase (LDH) median 1548 [IQR: 754–2379] vs. 363 [IQR: 325–443] U/L, p = 0.0001). Bacterial (n = 4) or viral (n = 1) infection was present in 5 out of 8 patients. LDH > 735 U/L predicted thromboembolic events/pump thrombosis with a positive predictive value of 88 %.

Conclusions

In patients with a CF-LVAD (HeartMate II), thromboembolic events and/or pump thrombosis are associated with symptoms and signs of acute haemolysis as manifested by a high LDH, elevated pump power and decreased pulse index, especially in the context of an infection.     

急性高原暴露后左心功能变化及与急性高原病的关系

目的：研究青年男性由平原急进高原后心脏血流动力学变化及其与急性高原病的关系。方法：分别检测218名健康青年男性在平原及急进高原24h内的血压、心卒和血氧饱和度,使用彩色多普勒超声仪检测左心功能;根据路易斯湖评分标准将受试者分为急性高原病纽（AMS组）和无急性高原病组（无AMS组）。结果：急性高原暴露后心率、舒张压、平均动脉压、左室射血分数、每搏输出量、每博指数、心输出量、心脏指数显著增加（P〈0．05）,血氧饱和度、左室收缩末容积则显著降低（P〈0．05）;急进高原后AMS组心率、收缩压、平均动脉压显著高于无AMS组（P〈0．05）,每博指数、左室舒张末容积显著低于无AMS组（P〈0．05）。结论：健康男性青年急性高原暴露后左心室收缩功能增强,左室舒张末容积、心率、每博指数可能作为预测急性高原病的参考指标。     

麻醉大鼠左心室插管新方法

目的：探索在0．014’’经皮冠状动脉（PTCA）指引导丝引导下行大鼠左心室插管的方法。方法：30只Wistar大鼠,先后在PTCA导丝引导经右侧颈外动脉,左侧颈外动脉插管至左心室并行血流动力学测定：结果：30只大鼠成功完成一次左心室重复插管,27只大鼠完成重复插管：结论：PTCA指引导丝引导下左心室插管安全并可重复操作。     

Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction

Acute myocardial infarction (AMI) is characterized by complex neuroendocrine activation. To investigate catestatin profiles, serial catestatin levels were determined by enzyme-linked immunosorbent assay in the first week after AMI in 50 patients. Catestatin levels reduced at admission and negatively correlated with heart rates; it increased significantly on the third day but remained decreased at 1 week and positively with blood pressure. In a subgroup of 20 patients admitted within 4?h after onset, circulating catestatin correlated inversely with norepinephrine. Catestatin might be involved in the course of AMI and act as a tool in monitoring the progression of AMI.